 NESS ZIONA, Israel, June 28, 2021 GLOBE NEWSWIRE -- Sol-Gel Technologies, Ltd. NASDAQ: SLGL, a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced positive pre-clinical data for SGT-510, its investigational topical roflumilast drug candidate and provided a corporate update. 